PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34952330-4	2022	RESULTS: RVEF (35.9% to 48.4%) increased and mPAP (42.1 mmHg to 33.1 mmHg) and PVR (551.8 to 377.7 dyn s/cm5) decreased after BPA (all p < 0.0001).	bisphenol A	126-129	phospholipid phosphatase 1	Mus musculus	45-49	
33569619-9	2021	CONCLUSIONS: Decreased dPA and dRA on CTPA could predict a decrease in mPAP after BPA, thus potentially eliminating unnecessary invasive catheterization.	bisphenol A	82-85	phospholipid phosphatase 1	Mus musculus	71-75	
33333638-14	2020	Conclusion: For inoperable patients with CTEPH, BPA can significantly improve disease severity, 6 MWD, heart function, decrease mPAP, PVR and improve lung perfusion, which is a safe and effective therapy.	bisphenol A	48-51	phospholipid phosphatase 1	Mus musculus	128-132	
32086654-6	2020	Significant reverse remodeling in the right-sided heart was observed after BPA, resulting in improvement of mPAP and pulmonary vascular resistance (RV area: from 15.0 +- 5.3 to 9.6 +- 3.0 cm2, p < 0.0001; RA area: from 17.3 +- 6.6 to 13.4 +- 3.8 cm2, p = 0.0002; RV free-wall strain: from 15.9 +- 5.6 to 21.2 +- 4.9%, p < 0.0001).	bisphenol A	75-78	phospholipid phosphatase 1	Mus musculus	108-112	
28291667-11	2018	The improvement in mPAP (p=0.002) and PVR (p=0.002) were significantly greater for BPA intervention when compared to medical therapy.	bisphenol A	83-86	phospholipid phosphatase 1	Mus musculus	19-23	
30790024-5	2019	Receiver operating characteristic (ROC) analyses were performed to determine the optimal cutoff of the strain at after BPA for detection of improved patients with decreased mean pulmonary artery pressure (mPAP) less than 30 mmHg and increased RVEF more than 50%.	bisphenol A	119-122	phospholipid phosphatase 1	Mus musculus	205-209